Study: Gene variant affects response to bowel cancer drugs

10/23/2008 | Bloomberg · Yahoo!

Advanced colon cancer patients with a mutation in the BRAF gene do not respond to ImClone Systems' Erbitux and Amgen's Vectibix, Italian researchers reported. The finding comes after earlier studies showed that another gene called KRAS can help identify patients who are most likely to benefit from both drugs.

View Full Article in:

Bloomberg · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA